Yongxin Ren

机构：Hong Kong Baptist University, Institute of Food Science & Technology, Hua Medicine (China), Jiangsu Province Hospital, Nanjing Medical University

发表论文 75 篇 · 总被引 1581 次 · h-index 17

代表论文

• Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor (2023 · Journal of Pharmacology and Experimental Therapeutics · 被引 10)
• Discovery of HMPL-306 (Ranosidenib), a New Potent and Selective Dual Inhibitor of Mutant IDH1 and 2 in Clinical Development for Cancer Treatment (2025 · ACS Medicinal Chemistry Letters · 被引 9)
• Isolation and characterization of bioactive collagen peptides from sea bass scales and their anti-photoaging effects (2025 · Food Chemistry · 被引 5)
• Abstract 543: Preclinical characteristic of HMPL-306, a CNS-penetrable dual inhibitor of mutant IDH1 and IDH2 (2023 · Cancer Research · 被引 4)
• Comparison of clinical efficacy of unilateral biportal endoscopic discectomy and percutaneous endoscopic interlaminar discectomy in the treatment of lumbar disc herniation at different segments (2025 · European Spine Journal · 被引 3)
• Abstract 2113: HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of MLL-rearranged and NPM1 mutant acute leukemia in preclinical models (2024 · Cancer Research · 被引 3)